biotech한국경제 IT (Hankyung)· 7/8/2026, 8:44:54 AM★ 8.0
When the NASDAQ Plummets... 'This Disease' Treatment Stock Soars
Global brain disease treatment companies and related ETFs are seeing significant price increases amid the NASDAQ's decline, driven by clinical successes and technological advancements.
💡 AI analysis: Success in overcoming the Blood-Brain Barrier (BBB) is transforming neuro-biotech from a high-risk niche into a structurally decoupled, high-alpha segment of the biotech market.
Related entities